BioReliance Corporation
14920 Broschart Road
Rockville
Maryland
20850
United States
Tel: 800-553-5372
Fax: 301-610-2590
Website: http://www.bioreliance.com/
Email: info@bioreliance.com
About BioReliance Corporation
BioReliance is the leading provider of GLP and cGMP compliant contract services supporting testing, development and manufacturing of biologics worldwide. Founded in 1947 as Microbiological Associates, BioReliance has operations in the United States, United Kingdom and Germany.
Products and services:
BioReliance testing services include: characterization of cell banks, release testing of bulk and final product, viral and DNA clearance studies, analytical services, genetic, mammalian and molecular toxicology, biodistribution studies and comprehensive testing for laboratory animals including serology and PCR testing on rodent and simian species.
BioReliance offers contract manufacturing services for mammalian cell derived viral therapeutics and agents expressed in E.coli and yeast. A full range of services is offered from process development, scale-up and qualification, bulk drug production, aseptic filling and final drug packaging. Regulatory support services include the preparation of Chemistry Manufacturing and Controls (CMC) sections of regulatory filings.
Last Updated: 05-01-2007
38 articles about BioReliance Corporation
-
GeoVax Announces Appointment of David Dodd as Chairman, President and Chief Executive Officer
8/14/2018
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that David A. Dodd has been appointed President and Chief Executive Officer, effective September 1, succeeding Robert McNally, PhD, who has announced his retirement.
-
BioReliance Corporation Licenses B-CLEAR Technology From Qualyst, Inc. Transporter Solutions For Drug Transporter Studies
4/21/2015
-
Conatus Pharmaceuticals Inc. And BioReliance Corporation Present Key Emricasan Preclinical Safety Results At Society Of Toxicology Annual Meeting
3/24/2015
-
BioReliance Corporation Introduces Advanced In Vitro ADME And Toxicology Services Designed To Improve Drug Safety And Efficacy
10/16/2014
-
Sigma-Aldrich Corporation Release: BioReliance Corporation Opens New U.S. Clearance Services Laboratories; Completes Global Facility Upgrade Plan
9/4/2013
-
Archie Cullen Named President of BioReliance Corporation
3/5/2013
-
Sigma-Aldrich Corporation Completes Acquisition of BioReliance Corporation
2/1/2012
-
Sigma-Aldrich Corporation to Acquire BioReliance Corporation for $350 Million Cash
1/9/2012
-
BioReliance Corporation Enhances Toxicology Expertise
9/13/2011
-
BioReliance Corporation Announces ToxCast Award
2/8/2011
-
Marilyn J. Aardema, PhD Joins BioReliance Corporation as Chief Scientific Officer, Toxicology
11/15/2010
-
BioReliance Corporation Launches a Validated Assay to Detect Calicivirus 2117 in Biological Samples
10/6/2009
-
BioReliance Corporation Establishes a Liaison Office in India
5/12/2009
-
Innovations in Toxicology at BioReliance Corporation: 23rd Annual Genotoxicity and Carcinogenicity Workshop
2/20/2009
-
BioReliance Corporation Announces Agreement with Barr Pharmaceuticals, Inc. to Supply Bulk Virus for the Manufacture of Adenovirus Vaccine for the U.S. Department of Defense
1/6/2009
-
BioReliance Corporation Announces First Commercial Use of HyMy(TM) Assay
11/20/2008
-
BioReliance Corporation Announces IMP Manufacturing Agreement with Provecs Medical GmbH
11/18/2008
-
BioReliance CorporationAnnounces that Sarah Sheridan, Ph.D. Will Deliver a Poster Presentation at the 16th Annual European Society of Gene and Cell Therapy Conference
11/13/2008
-
BioReliance Corporation Introduces New Protein Array Platform -- ReliArray(TM)
11/7/2008
-
BioReliance Corporation Appoints Andrew Paterson Ph.D. as Senior Director/General Manager for UK Operations
10/14/2008